<p>Oxidative stress and biochemical markers in prenatally androgenized sheep after neonatal treatment with GnRH agonist</p>

Abstract

Background Disruption of the balance between the production of ROS and their removal through enzymatic and non-enzymatic (antioxidant) processes has been proposed as a new mechanism in the pathology of polycystic ovary syndrome (PCOS). Evidence from animal models of PCOS (prenatally androgenized sheep) has suggested that treatment with insulin sensitizers, but not antiandrogens, can reduce increases in ROS. Materials and methods In the present study, we investigated the effects of neonatal treatment with a gonadotropin-releasing hormone (GnRH) agonist (leuprolide acetate) on prenatally androgenized sheep with testosterone propionate to determine its impact on oxidative stress molecules (ferric reducing antioxidant power [FRAP], advanced oxidation protein product [AOPP], nitric oxide [NOx], albumin) at 8, 12, and 18 months of age. Results Androgenized ewes (but not leuprolide-treated ewes) showed reduced total cholesterol levels associated with a decrease in the ratio of visceral to subcutaneous adiposity (adjusted to abdominal area) as determined by computed tomography. In androgenized ewes at 12 months of age, an increase in subcutaneous fat and relative decrease in the visceral fat compartment did not affect the expression of REDOX markers. At 18 months of age, however, the levels of NOx metabolites decreased in androgenized animals, but remained close to normal in ewes subjected to neonatal treatment with leuprolide acetate. Other oxidative stress parameters (FRAP, AOPP, albumin) did not vary among groups. Conclusion Our results demonstrate that the GnRH agonist leuprolide (as a single dose after birth) had weak effects on markers of the oxidative stress balance.

Urinary Metabolite Signatures for Predicting Elderly Stroke Survivors with Depression

“…Firstly, we only adjusted the HDRS score, age, BMI and sex to avoid the potential influences of socio-demographic data on our findings; the effects of other sociodemographic variables, such as marital status and levels of education, were needed future studies to assess. Secondly, all the included stroke survivors received medications to treat stroke; because the medications might affect the metabolomics profiles, 36 further researches were needed to support and validate our conclusions. Thirdly, the antidepressive effects of taking supplements of phenylalanine were not validated here; future studies should further explore whether taking supplements of phenylalanine can prevent depression in stroke survivors.…”